Frequency of concurrent use of warfarin with potentially interacting drugs

Pharmacotherapy

Volumn 24, Issue 12 I, 2004, Pages 1668-1674

  Wittkowsky, Ann K ^a,b   Boccuzzi, Stephen J ^c   Wogen, Jenifer ^d   Wygant, Gail ^b   Patel, Pankaj ^b   Hauch, Ole ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c AETNA   (United States)

^d AstraZeneca LP ^*

Author keywords

Anticoagulation; Bleeding; Drug interactions; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMIODARONE; AZITHROMYCIN; CARBAMAZEPINE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; CYCLOOXYGENASE 2 INHIBITOR; DOXYCYCLINE; ERYTHROMYCIN; FENOFIBRATE; FLUCONAZOLE; FLUINDOSTATIN; FLUOXETINE; METRONIDAZOLE; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; OFLOXACIN; PARACETAMOL; PAROXETINE; PROPAFENONE; QUINIDINE; QUININE; SERTRALINE; STATIN; SUCRALFATE; THYROID HORMONE; TRAZODONE; UNINDEXED DRUG; WARFARIN;

AGED; BLEEDING; COHORT ANALYSIS; DATA BASE; FEMALE; HUMAN; INTERNATIONAL STANDARD UNIT; MALE; POLYPHARMACY; PRESCRIPTION; PROTHROMBIN TIME; RETROSPECTIVE STUDY; REVIEW;

ADULT; AGED; ANTICOAGULANTS; COHORT STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; WARFARIN;

EID: 9644307858     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.17.1668.52338     Document Type: Review

References (20)

1. RxList LLC. Warfarin. Available from http://www.rxlist.com. Accessed February 13, 2003.
2. Anonymous. Physicians' desk reference, 58th ed. Montvale, NJ: Thompson PDR, 2004:1048-52.
3. Matchar DB, Samsa GP, Cohen SJ, Oddone EZ, Jurgelski AE. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med 2002;113:42-51.
4. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-6.
5. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897-902.
6. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(1 suppl):8S-21.
7. Bristol-Myers Squibb Company. Coumadin (warfarin) package insert. Princeton, NJ; 2003.
8. Hafner JW Jr, Belknap SM, Squillante MD, Bucheit KA. Adverse drug events in emergency department patients. Ann Emerg Med 2002;39:258-67.
9. Gaddis GM, Holt TR, Woods M. Drug interactions in at-risk emergency department patients. Acad Emerg Med 2002;9:1162-7.
10. Linjakumpu T, Hartikainen S, Klaukka T, Veijola J, Kivela SL, Isoaho R. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol 2002;55:809-17.
11. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002;287:337-44.
12. Tatro D. Drug interaction facts. St. Louis, MO: Wolters Kluwer, 2004:xiv-vi.
13. Hansten P, Horn J. Drug interactions: analysis and management. St. Louis, MO: Wolters Kluwer, 2004:xiii-iv.
14. Howard PA, Ellerbeck EF, Engelman KK, Patterson KL. The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. Pharmacoepidemiol Drug Saf 2002;11:569-76.
15. Siguret V, Esquirol C, Debray M, Gouin I, Andreux JP, Pautas E. Excess antivitamin K in elderly hospitalised patients aged over 70: a one-year prospective survey. Presse Med 2003;32:972-7.
16. Ebbesen J, Buajordet I, Erikssen J, et al. Drug-related deaths in a department of internal medicine. Arch Intern Med 2001;161:2317-23.
17. Kurnik D, Lubetsky A, Loebstein R, Almog S, Halkin H. Multivitamin supplements may affect warfarin anticoagulation in susceptible patients. Ann Pharmacother 2003;37:1603-6.
18. Horstkotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J Thromb Thrombolysis 1998;5(suppl 1):19-24.
19. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003;289:1107-16.
20. Barat I, Andreasen F, Damsgaard EM. The consumption of drugs by 75-year-old individuals living in their own homes. Eur J Clin Pharmacol 2000;56:501-9.